Medical News Feed
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | Blood coagulation factor VIII (human), glycoform a. |
| Generic Name : | Factor VIII [octocog alfa] |
| Drug description : | Blood coagulation factor VIII (human), glycoform a produced from genetically engineered baby hamster kidney cells containing a cloned human Factor VIII gene. Powder in vials plus WFI and administration set. |
| Presentation : | Powder for injection, octocog alfa with nominal haemophilic factor activities of 250 i.u. , 500 i.u. , 1,000 i.u. |
| Indications : | Congenital Factor VIII deficiency (haemophilia A) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors. Treatment can be continued in patients who develop Factor VIII inhibitors and who continue to respond to Kogenate. Kogenate does not contain von Willebrand Factor and hence is not indicated in von Willebrand's disease. |
| Adult Dosage : | 1 - 2 mL/minute by slow 1 - 2 mL/minute by slow intravenous infusion according to body weight, severity of haemorrhage and presence of inhibitors. Refer to Summary of Product Characteristics. |
| Child Dosage : | 1 - 2 mL/minute by slow intravenous infusion according to body weight, severity of haemorrhage and presence of inhibitors. Refer to Summary of Product Characteristics. |
| Contra Indications : | Known allergic reactions to constituents of preparation. Known hypersensitivity to mouse or hamster protein. |
| Special Precautions : | Pregnancy, lactation. Monitor for Factor VIII inhibitors and activity regularly. If hypersensitivity occurs, discontinue treatment. |
| Interactions : | None known. |
| Adverse Reactions : | Local reactions at injection site (eg, burning, transient erythema, rash), hypersensitivity (chest tightness, dizziness, mild hypotension, nausea). Anaphylactic shock. Development of inhibitors. |
| Manufacturer : | Bayer |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org